TO THE EDITOR
Although allogeneic stem cell transplantation from a human leukocyte antigen (HLA)-identical related donor offers a potential cure for patients with acute lymphoblastic leukemia (ALL), a suitably matched related donor is unavailable for approximately two-thirds of patients. Recently, umbilical cord blood from unrelated donors have been used as an alternative stem cell source for adult patients with hematological disorder.
1-8 However, there have been no reports detailing the results of adult ALL patients treated with cord blood transplantation (CBT). Therefore, the role of unrelated CBT is not well defined in adult patients with ALL.
Between October 2000 and November 2003, 13 adult patients with ALL were treated with unrelated CBT at the Institute of Medical Science, University of Tokyo. Analyses of data were performed on April 1, 2004. In all, 10 patients received four fractionated 12 Gy total body irradiation (TBI) and 120 mg/kg cyclophosphamide (CY), which was administered intravenously over 2 h at a dose of 60 mg/kg once daily on days À4 and À3 or days À3 and À2. Two patients (case 9, 11), who had a cardiac damage as a result of extensive prior therapies, received four fractionated 12 Gy TBI on days -8 and -7, cytosine arabinoside (Ara-C) 3 g/m 2 every 12 h on days -5 to -2 (total dose 24 g/m 2 ), and fludarabine (Flu) 30 mg/m 2 once daily on days À5 to -3. One patient received four fractionated 12 Gy TBI on days -8 and -7, Flu 30 mg/m 2 once daily on days -6 to -4, and melphalan 70 mg/m 2 once daily on days -3 and -2 as conditioning. At 2 or 3 days after the completion of conditioning, patients received a CBT. All patients received standard cyclosporine (CyA) and methotrexate (MTX) as a graft-versushost disease (GVHD) prophylaxis. CyA was given every day starting on day À1 at a dose of 3 mg/kg/day. MTX 15 mg/m 2 intravenously was given on day 1 and 10 mg/m 2 on days 3 and 6. Both acute and chronic GVHD were graded according to the Seattle criteria. All patients received G-CSF (Lenograstim, 5 mg/kg/day) by intravenous infusion starting on day 1 until durable granulocyte recovery was achieved. Cord blood unit was selected according to the number of nucleated cells per recipient's weight and HLA compatibility (HLA-A and -B by serology and HLA-DRB1 high-resolution DNA typing). The chimerism status after CBT was determined either by fluorescence in situ hybridization with a Y chromosome probe for sex-mismatched CBT or by polymerase chain reaction DNA typing of HLA antigen for HLA-mismatched CBT. No patients had a related or unrelated bone marrow donor available at the time of transplantation. Written informed consent for treatment was obtained from all patients. The probability of disease-free survival (DFS) was estimated by the Kaplan-Meier method.
The characteristics of the 13 patients and cord blood units are shown in Tables 1 and 2 . Among the patients, the median age was 36 years (range, 18-53 years), the median weight was 56 kg (range, 40-71 kg) , and the median number of infused nucleated cells, measured before freezing, was 2.89 Â 10 7 /kg (range, 1.81-3.66 Â 10 7 /kg). Among the 13 patients, six were beyond CR1 at transplantation. Among the seven patients in CR1, three were Philadelphia chromosome (Ph) positive and one was t(4;11). A total of 11 patients had myeloid reconstitution and median time to more than 0.5 Â 10 9 /l absolute neutrophil count was 20 days (range, 17-26 days). A self-sustained hemoglobin greater than 8.5 g/dl was achieved in eight patients at a median time of 52 days (range, 43-90 days). A self-sustained platelet count more than 50 Â 10 9 /l was achieved in 10 patients at a median time of 48 days (range, 40-106 days). All patients with myeloid reconstitution showed full donor chimerism at the time of first bone marrow examination after CBT. Acute GVHD occurred in 11 of 11 evaluable patients. The grading of acute GVHD was grade I in five patients and grade II in six. Chronic GVHD occurred in seven of eight evaluable patients. Among seven chronic GVHD patients, one patient was extensive type. Among 13 patients, five patients died. One patient died of hepatic venoocclusive disease on days 18. Four patients died of relapse on days 803, 81, 339, and 380, respectively. Primary graft failure occurred in one patient (Case 12), who received the second CBT on day 40 after the first transplantation and engrafted. Case 12 received Flu 40 mg/m 2 once daily on days -4 to -2 as conditioning for the second CBT. Case 12 is alive in complete remission at the time of writing. Seven patients are alive and free of disease between 133 and 1253 days after transplantation (Table 2) . With a median follow-up of 308 days, the probability of DFS was 55.9% (Figure 1 ).
Several studies have suggested the promising results of unrelated CBT for adult patients. [1] [2] [3] [4] [5] [6] [7] [8] In the report of Laughlin et al, 1 68 adult patients received CBT. Among the 68 patients, 15 had ALL. In the report of the Eurocord group, 2 108 adult patients received CBT. Among the 108 patients, 32 had ALL. However, these two reports did not detail the preparative regimens and prophylaxis against GVHD, and the results of transplantation for ALL patients. Barker et al 5 reported the results of 43 adult patients who received CBT after reduced-intensity preparative regimens. Among the 43 patients, only three had ALL. Sanz et al 3 reported the results of 22 adult patients who received CBT following a standardized preparative and GVHD regimen. Among the 22 patients, six had ALL. Of six ALL patients, three remain alive and disease free and three died 10 to 150 days after CBT. Recently, Long et al 8 reported the results of 57 adult patients who received CBT at Duke University. Although among the 57 patients 13 had ALL, the details of outcome of ALL patients were not described. At present, therefore, the role of unrelated cord blood as an alternative stem cell source is not well defined in adult ALL patients eligible for conventional conditioning regimens. Although the DFS rate of our 13 patients in this study was relatively lower than our previous reports, 6,7 which included 31 adult patients with advanced myelodysplastic syndrome and de novo acute myeloid leukemia who received unrelated CBT, the rate in this study was similar to other published reports of adult ALL patients who received HLA-matched sibling allogeneic transplantation. As the number of patients was small, the influence of cord blood cell number and HLA matching on transplant outcome was not clear. Also, we could not conclude that unrelated cord blood can act as an alternative stem cell source in adult patients with ALL. However, these results suggest that adult ALL patients without suitable related or unrelated bone marrow donors should be considered as candidates for CBT and provide the rationale for a larger clinical study of CBT. Neutrophil recovery was defined as the first of 3 consecutive days during which the absolute neutrophil count in the blood was at least 0.5 Â 10 9 /l. Platelet recovery was defined as the first of 3 consecutive days during which the platelet count in the blood was at least 50 Â 10 9 /l without transfusion support. Reticulocyte (1%) and hemoglobin level (8.5 g/dl) recovery were defined as the first of 7 consecutive days without transfusion support. Case 12 received second cord blood transplantation on day 40 after first transplantation and is alive in complete remission at the time of writing. Case 2, 5, 7 and 8 relapsed on day 244, day 34, day 95, and day 78, respectively.
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We thank the physicians and nurses who cared for patients in this study. Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia Leukemia (2004 Leukemia ( ) 18, 1907 Leukemia ( -1909 Chronic myeloid leukemia (CML) would appear to be the ideal disease for exploring nonmyeloablative stem cell transplantation (NST), at least in the early chronic phase (CP) 1 (Deininger MWN et al. Bone Marrow Transplant 2002; 29: 31 (abstract) ). However, NST in advanced phases will not routinely replace the conventional myeloablative regimen due to the higher relapse rate. Although imatinib, which is an inhibitor of BCR-ABL tyrosine kinase, is highly effective in Philadelphia (Ph) chromosome-positive CML, 2 relapses during the imatinib treatment also have been observed in the accelerated phase (AP) and even in some patients with CP CML.
3 Therefore, additional curative modalities will be needed in patients who have achieved the optimum responses after an imatinib treatment in advanced phases of CML. There have been a few case reports using imatinib for allogeneic transplantation.
4,5 So far, the precise impact of a long-term pretransplant treatment with imatinib on engraftment, the transplant-related morbidity and mortality (TRM), graft-versus-host disease (GVHD), relapse, and survival has not been reported.
To know the exact role of imatinib prior to NST, a total of 20 CML patients were evaluated. Of these, 10 patients (pre-NST imatinib group) were treated with imatinib and the disease phases at administration were three in CP and seven in AP. Imatinib was begun with oral doses of 400-600 mg daily for the pre-NST imatinib group and the doses were adjusted according to a previously published guideline. 6 The imatinib treatment continued until complete cytogenetic response (CCR) or the major response for more than 6 months was achieved, and stopped on day À10 before starting the conditioning regimen. After a median imatinib treatment of 9.5 (range 6-12) months, nine achieved a CCR and one returned to CP at a transplant. The 
